Wegener's granulomatosis: Current and upcoming therapies

Arthritis Research and Therapy

Volumn 5, Issue 4, 2003, Pages 180-191

  Langford, Carol A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Granulomatosis; Treatment; Vasculitis; Wegener

Indexed keywords

15 DEOXYSPERGUALIN; ADENOSINE; ALEMTUZUMAB; ALKYLATING AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; DIHYDROFOLATE REDUCTASE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; MESNA; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; SPERGUALIN DERIVATIVE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ABDOMINAL PAIN; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLADDER CARCINOMA; BLADDER INJURY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; INFERTILITY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER INJURY; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASIA; PATHOPHYSIOLOGY; PLASMAPHERESIS; PNEUMONIA; RASH; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; SUBGLOTTIC STENOSIS; SURVIVAL TIME; TREATMENT PLANNING; WEGENER GRANULOMATOSIS;

CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; WEGENER GRANULOMATOSIS;

EID: 0043175217     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Walton E: Giant cell granuloma of the respiratory tract (Wegener's Granulomatosis). Br Med J 1958, 2:265-270.
2. Fauci A, Wolff S: Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine 1973, 52: 535-561.
3. Luqmani RA: Assessing disease activity in the systemic vasculitides. Curr Opin Rheumatol 2002, 14:23-28.
4. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-494.
5. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Detree F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198.
6. Langford CA, Talar-Williams C, Barron KS, Sneller MC: A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999, 42:2666-2673.
7. Jayne D: Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001, 13:48-55.
8. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA: The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996, 39:87-92.
9. Hollander D, Manning RT: The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967, 67:393-398.
10. Hoffman GS: Wegener's granulomatosis. Curr Opin Rheumatol 1993, 5:11-17.
11. Fauci A, Haynes B, Katz P, Wolff S: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
12. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, Heller M, Gross WL: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032.
13. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996, 124:477-484.
14. Falk RJ, Hogan S, Carey TS, Jennette JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990, 113: 656-663.
15. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS: Treatment of Wegener's granulomatosis with intermittent highdose intravenous cyclophosphamide. Am J Med 1990, 89: 403-410.
16. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, Duncker G, Gross WL: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994, 37:919-924.
17. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, Michael J, Savage CO, Bacon PA: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997, 90:401-409.
18. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R: Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998, 41:1835-1844.
19. de Groot K, Adu D, Savage CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001, 16:2018-2027.
20. Langford CA, Talar-Williams C, Barron KS, Sneller MC: Use of a cyclophosphamide induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003, 114: 463-469.
21. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002, 47:326-332.
22. Chan ES, Cronstein BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4:266-273.
23. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992, 35:6112-6118.
24. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995, 38:608-613.
25. Langford CA, Sneller MC, Hoffman GS: Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997, 23:841-853.
26. Langford CA, Talar-Williams C, Sneller MC: Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000, 43:1836-1840.
27. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL: Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998, 25:492-495.
28. Stone JH, Tun W, Hellman DB: Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999, 26:1134-1139.
29. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999, 10:1965-1971.
30. Allen NB, Caldwell DS, Rice JR, McCallum RM: Cyclosporin A therapy for Wegener's granulomatosis. Adv Exp Med Biol 1993, 336:473-476.
31. Haubitz M, Koch KM, Brunkhorst R: Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998, 13:2074-2076.
32. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, Peter HH, Kalden JR, Gobel U, Drexler JM, Hotta O, Nowack R, van der Woude FJ: 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003, 14:440-447.
33. Jayne DR, Esnault VL, Lockwood CM: ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993, 6:207-219.
34. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991, 337:1137-1139.
35. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL: Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995, 101:2-7.
36. Jayne DR, Lockwood CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996, 35:1150-1153.
37. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000, 93:433-439.
38. DeRemee RA, McDonald TJ, Weiland LH: Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985, 60:27-32.
39. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994, 120:12-17.
40. Popa ER, Stegeman CA, Kallenberg CG, Cohen Tervaert JW: Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 2002, 4:77-79.
41. Hoffman GS: Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis 1996, 13:249-252.
42. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL: Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996, 89:15-23.
43. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996, 335:16-20.
44. Langford CA, Sneller MC, Hallahan CW, Hoffman GS, Kammerer WA, Talar-Williams C, Fauci AS, Lebovics RS: Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996, 39:1754-1760.
45. Gaskin G, Pusey CD: Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apheresis 2001, 5:176-181.
46. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H: Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Q J Med 1996, 89:903-912.
47. Ludviksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, Fauci AS, Strober W: Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998, 160:3602-3609.
48. Csernok E, Trabandt A, Müller A, Wang GC, Moosig F, Paulsen J, Schnabel A, Gross WL: Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999, 42:742-750.
49. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS: Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001, 44:1149-1154.
50. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, Gause A: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002, 41:1303-1307.
51. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR: Safety and efficacy of TNFalpha blockade in relapsing vasculitis [letter]. Ann Rheum Dis 2002, 61:559.
52. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
53. Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840.
54. Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998, 41:1521-1537.
55. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
56. Falk RJ, Jennette JC: ANCA are pathogenic - oh yes they are! J Am Soc Nephrol 2002, 13:1977-1979.